Skip to main content

Table 1 Demographic and clinical characteristics-grouped by disease duration

From: Efficacy of early intervention on the bowel damage and intestinal surgery of Crohn’s disease, based on the Lémann index

Variable Total patients (n = 154) Early CD(n = 70) Late CD(n = 84) P value
Gender(male: female) 103: 51 44: 26 58: 26 0.42
Median age on set of CD, years 24.5 [17.0–29.0] 25.0 [17.0–28.0] 24.0 [15.5–31.0] 0.56
Median age at enrollment, years 29.0 [23.0–36.0] 26.0 [19.8–30.5] 33.0 [27.00–39.8]  < 0.001
Median disease duration, years 4.5 [1.0–7.0] 1.0 [0.5–2.0] 7.0 [4.0–9.0]  < 0.001
Montreal (Age)     
 A1 (16 years or younger) 16 (10.4%) 8 (11.4%) 8 (10.7%) 0.43
 A2 (17‐40 years) 114 (74.0%) 53 (75.7%) 61 (72.6%) 0.42
 A3 (more than 40 years) 24 (15.6%) 9 (12.9%) 15 (17.9%) 0.36
Montreal L (location)     
 L1 (ileal) 72 (47.1%) 38 (54.3%) 32 (38.1%) 0.43
 L2 (colonic) 9 (5.8%) 3 (4.3%) 6 (7.1%) 0.19
 L3 (ileocolonic) 71 (46.1%) 26 (37.1%) 45 (53.6%) 0.16
 L4 (upper GI) 31 (20.1%) 13 (18.6%) 19 (22.6%) 0.60
Montreal B (Behavior)     
 B1 94 (61.0%) 46 (65.7%) 48 (57.1%) 0.26
 B2 40 (26.0%) 17 (24.3%) 23 (27.4%) 0.51
 B3 26 (16.9%) 9 (12.9%) 17 (20.2%) 0.53
Perianal disease 69 (44.8%) 37 (52.9%) 32 (38.1%) 0.07
Previous surgical resection 27 (17.5%) 7 (10.0%) 20 (23.8%) 0.02
Previous medical treatments     
 Steroids 24 (15.6%) 9 (12.9%) 15 (17.9%) 0.08
 Immunomodulators 43 (27.9%) 0 (0%) 43 (51.2%)  < 0.001
 5-ASA 41 (26.7%) 18 (25.7%) 23 (27.4%) 0.62
Smoking habit 12 (7.8%) 4 (5.7%) 8 (9.5%) 0.23
Baseline serological markers     
 CRP, mg/L 4.3 [0.5–15.3] 6.16 [0.4–24.9] 5.2 [0.5–13.1] 0.12
 ESR, mm/h 22.0 [12.0–45.0] 19.0 [12.0–42.0] 24.0 [13.0–49.0] 0.10
 ALB, g/L 38.6 [31.5–43.6] 38.7 [32.1–42.6] 38.4 [30.6–44.7] 0.70
 HB, g/L 125.0 [101.0–141.3] 126.5 [105.0–140.3] 124.0 [95.25–142.0] 0.24
 PLT, × 10^9/L 240.0 [196.0–314.3] 247.0 [197.0–342.0] 229.0 [193.8–297.3] 0.12
Current serological markers     
 CRP, mg/L 0.6 [0.2–3.0] 0.55 [0.2–2.2] 0.57 [01.7–3.4] 0.61
 ESR, mm/h 14.0 [3.0–22.0] 12.0 [2.0–20.0] 15.0 [3.0–24.0] 0.16
 ALB, g/L 42.0 [32.7–46.0] 42.6 [33.4–46.3] 41.05 [30.28–45.6] 0.27
 HB, g/L 132.0 [113.0–147.0] 136.0 [122.0–149.3] 126.5 [111.0–146.8] 0.27
 PLT, × 10^9/L 225.5 [199.0–286.0] 225.0 [198.0–283.0] 228.0 [199.0–300.0] 0.73
Inclusion LI 6.2 [2.4–10.7] 6.3 [1.7–10.5] 5.9 [3.0–11.0] 0.67
Follow up LI 4.5 [1.7–9.4] 3.4 [1.6–7.5] 5.2 [2.0–10.5] 0.02
Follow up time (months) 17.0 [13.2–23.3] 15.0 [13.0–25.0] 18.5 [13.5–24.0] 0.18
CD-related bowel surgery 22 (14.3%) 5 (7.1%) 17 (20.2%) 0.001
Stabilized 31 (20.1%) 13 (18.6%) 18 (21.4%) 0.29
Improved 79 (51.3%) 43 (61.4%) 36 (42.9%)  < 0.001
Deteriorated 44 (28.6%) 14 (20%) 30 (35.7%)  < 0.001
  1. Data are expressed as number (%) or median[IQR]
  2. B1, nonstricturing nonpenetrating; B2, stricturing; B3, penetrating; 5-ASA, 5-aminosalicylic; CRP, C-reactive protein; ESR, erythrocyte sedimentation; ALB, Albumin; HB, Hemoglobin; PLT, Platelet; LI, Lémann index. Patients whose LI was unchanged were defined as “stabilized”, those with a decreased LI as “Improved”, and those with an increased LI as “Deteriorated”